Sector News

Amgen veteran Reshma Kewalramani promoted to Vertex CMO

February 27, 2018
Life sciences

Having spent just a year at Vertex, and after a major 12-year stint at Amgen, Reshma Kewalramani, M.D., has been promoted to chief medical officer (CMO) and EVP of global medicines development and medical affairs at the company.

Kewalramani’s promotion, coming after being named as senior VP of late development exactly a year ago, comes as its CMO Jeffrey Chodakewitz, M.D., is to retire. Kewalramani takes over the role on April 1, while Chodakewitz, a 20-year Merck vet before joining Vertex back in 2014, will retire and serve as senior advisor through to early 2019.

“I would like to personally thank Jeff for his leadership and dedication to improving the lives of people with cystic fibrosis and other serious and life-threatening diseases,” said Jeffrey Leiden, M.D., Ph.D., Vertex’s CEO.

“He has played a critical role in leading multiple successful clinical development efforts at Vertex, and I’m pleased that we will continue to benefit from his guidance as a senior advisor over the next year as he transitions to retirement.

“I’m also delighted that Reshma has agreed to succeed Jeff as our Chief Medical Officer. Reshma’s depth of medical knowledge, paired with her experience and proven track record as a clinical leader at Vertex, makes her an ideal successor to Jeff. I look forward to working with Reshma to continue to advance our clinical development pipeline in cystic fibrosis and other serious diseases.”

Kewalramani spent more than 12 years at Amgen, where she most recently served as VP and head of the U.S. medical organization, before moving to Vertex.

Her role will largely be focused around its cystic fibrosis combo pipeline, which has been generating some positive buzz of late, and some earlier work in this field in MRNA and gene editing.

It’s also doing work on acute spinal injury, which is in phase 2, as well as pain. It also has work in cancer and influenza, with those out licensed to Merck KGaA and Janssen, respectively.

But nearly a year ago, it also slimmed down its R&D staffers, with sources saying last March that it was planning to close a site in Canada, cutting 70 jobs, and trim its headcount in Boston, according to a source close to the company.

“It’s a privilege to work at a company with such a relentless focus on science and deep commitment to improving the lives of patients and their families,” said Kewalramani.

“I am excited to assume the role of CMO and continue our important work to help more people with cystic fibrosis and other serious diseases alongside the talented team at Vertex.”

Vertex, with a $42.5 billion market cap, was up around 1.4% in this morning’s trading.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach